Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06452706 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Name: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer — clinical trial record (NCT06452706)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Started2024-11-14

View on ClinicalTrials.gov ↗

Record status

This record was last updated November 19, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2024-11-18

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2024-11→confirmed 2024-11-14

Study sites15→16

2024-10-30

Study Status, Contacts/Locations v1

Start date2024-07→2024-11

Study sites10→15

2024-06-06

Original filing

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

38 trials monitored

See all monitored trials

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.

Trial Details

NCT Number	NCT06452706
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions	Breast Cancer
Enrollment	42 participants
Start Date	2024-11-14
Primary Completion	2026-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2024-11-19